Compare Marqeta Inc (MQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Neurocrine Biosciences Inc — how do they compare? Marqeta Inc trades at $15.52 (market cap $1.62B), while Neurocrine Biosciences Inc trades at $151.61 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 10.2× Marqeta Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MQ | NBIX | |
|---|---|---|
Market Cap | $1.62B | $16.46B |
Sector | Technology | Health |
52-Week High | $26.00 | $185.50 |
52-Week Low | $15.04 | $123.10 |
Enterprise Value | $935.36M | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
